M
This preclinical stage biotech startup is developing oral therapeutics that selectively modulate immune cell function to treat complex autoimmune diseases such as glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. By targeting specific immune cell lineages, the company aims to provide effective treatments for significant unmet medical needs in autoimmune disorders.
Basel, Switzerland
Updated 2 months ago
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This preclinical stage biotech startup is developing oral therapeutics that selectively modulate immune cell function to treat complex autoimmune diseases such as glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. By targeting specific immune cell lineages, the company aims to provide effective treatments for significant unmet medical needs in autoimmune disorders.